Previsão

O preço-alvo médio dos analistas é € 11,20 (-31,58%). A mediana é € 8,62 (-47,34%).

Comprar	0
Manter	5
Vender	1

Notícias Ir para o feed de notícias

ARCHIMED completes acquisition of ZimVie at $19.00 per share

ARCHIMED has completed the acquisition of dental implant maker ZimVie at $19.00 per share, valuing the company at about $536 million. ZimVie’s NASDAQ listing was terminated; the stock had returned 102% in the six months prior to the transaction. ZimVie generates annual revenues of $443 million, has a gross margin of 65.3%, and shows solid liquidity with a current ratio of 2.37. » Mais em de.investing.com
ZimVie expands through distribution partnership with Osstem Implant and merger agreement with ARCHIMED

ZimVie has entered into an exclusive distribution partnership with Osstem Implant for the Chinese market to sell its dental implants there. In addition, a merger agreement with investment firm ARCHIMED worth around 730 million US dollars has been announced, which includes a cash premium for shareholders. Analysts responded differently to the acquisition, while ZimVie reported mixed business results for the first quarter. » Mais em de.investing.com
ZimVie to be taken private after $730 million acquisition by ARCHIMED

ZimVie's shares jumped 122% after it was announced that the dental implant company will be acquired by investment firm ARCHIMED for approximately $730 million. Shareholders will receive $19 per share, representing a 99% premium over the 90-day average price. Once the transaction is completed, ZimVie will become a privately held company and its shares will no longer be traded on NASDAQ. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, ZimVie Aktie registou receitas de € 98,98 mi e um ganho líquido de -€ 3,35 mi

(EUR)	junho de 2025	YoY
Receitas	98,98 mi	-
Ganho bruto	63,89 mi	-
Ganho líquido	-3,35 mi	-
EBITDA	10,8 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 461,61 mi
Número de ações	28,21 mi
Máximo/mínimo de 52 semanas	€ 16,38 - € 7,02
Dividendos	Não
Beta	2,06
PER (PE Ratio)	-99,95
PEG (PEG Ratio)	-0,68
P/VC (PB Ratio)	1,29
P/V (PS Ratio)	2,34

Perfil da empresa

ZimVie Inc., ein Medizintechnikunternehmen, entwickelt, produziert und vertreibt ein Portfolio von Produkten und Lösungen zur Behandlung einer Reihe von Wirbelsäulenpathologien und zur Unterstützung von Zahnersatz- und Restaurationsverfahren weltweit. Das Unternehmen bietet Zahnimplantatsysteme, Prothetik- und Abutmentprodukte, chirurgische Instrumente und Kits, Knochentransplantate, Barrieremembranen, Allografts und Kollagen-Wundversorgungsprodukte, Intraoralscanner, virtuelle Behandlungsplanungsdienste, Lösungen für die schablonengeführte Chirurgie, CAD/CAM-Workflowsysteme und patientenspezifische Restaurationskomponenten und Intraoralscanner sowie Wirbelsäulenfusionsimplantate und Instrumente für verschiedene Wirbelsäulenverfahren, Biologika und Knochenheilungstechnologien. Das Unternehmen bietet auch MIS-Lösungen wie Vital MIS und Timberline sowie Lösungen zur Bewegungserhaltung wie Mobi-C und The Tether an. ZimVie Inc. wurde im Jahr 2021 gegründet und hat seinen Hauptsitz in Westminster, Colorado.

Nome	ZimVie Aktie
CEO	Vafa Jamali
Sede	Palm Beach Gardens, co EUA
Site	zimvie.com
Setor	Cuidados de saúde
Indústria	Cuidados de saúde: equipamentos e produtos
Entrada em bolsa	23/08/2017
Colaboradores	1.770